시장보고서
상품코드
1274279

세계의 의료용 모르핀 시장 전망(-2030년)

Medical Morphine Market Forecast to 2030

발행일: | 리서치사: Market Research Future | 페이지 정보: 영문 100 Pages | 배송안내 : 문의

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 의료용 모르핀 시장 규모는 예측 기간 동안 연평균 7.20%의 건전한 성장을 보일 것으로 예상됩니다. 심혈관 질환, 관절염, 악성 종양 등 다양한 질병에 대한 진통제 치료 증가는 주로 시장 발전에 기여하고 있습니다. 또한 고령 인구 증가는 환자 인구의 확대와 시장 진입을 촉진하고 있습니다.

이 보고서는 세계 의료용 모르핀(Medical Morphine) 시장을 조사 분석하여 시장 역학, 지역 및 부문 분석, 기업 프로파일 등을 제공합니다.

목차

제1장 보고서 프롤로그

제2장 시장 서론

제3장 조사 방법

제4장 시장 역학

  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 거시경제 지표
  • 기술 동향과 평가

제5장 시장 요인 분석

  • Porter의 Five Forces 분석
  • 밸류체인 분석
  • 투자 실현 가능성 분석
  • 가격 분석

제6장 세계의 의료용 모르핀 시장 : 투여 경로별

  • 서론
  • 경구
  • 주사
  • 기타

제7장 세계의 의료용 모르핀 시장 : 용도별

  • 서론
  • 관절염
  • 심근경색
  • 신장결석
  • 설사
  • 기타

제8장 세계의 의료용 모르핀 시장 : 유통 채널별

  • 서론
  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 기타

제9장 세계의 의료용 모르핀 시장 : 최종사용자별

  • 서론
  • 병원 및 진료소
  • 외래수술센터(ASC)
  • 홈케어
  • 기타

제10장 세계의 의료용 모르핀 시장 : 지역별

  • 서론
  • 미국
    • 북미
    • 남미
  • 유럽
    • 서유럽
    • 동유럽
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 대한민국
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 아랍에미리트(UAE)
    • 사우디아라비아
    • 오만
    • 쿠웨이트
    • 카타르
    • 중동 및 아프리카

제11장 기업 상황

  • 서론
  • 시장 점유율 분석
  • 주요 발전·전략

제12장 기업 개요

  • MALLINCKRODT PHARMACEUTICALS
  • ALCALIBER S.A.
  • PURDUE PHARMA L.P.
  • PFIZER INC.
  • JOHNSON MATTHEY FINE CHEMICALS
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • VERVE HEALTH CARE LTD.
  • TAJ PHARMACEUTICALS LIMITED
  • NORTHEAST PHARM
  • MANUS AKTTEVA BIOPHARMA LLP

제13장 부록

LSH 23.05.25

Medical Morphine Market Forecast till 2030

Market Overview

The Medical Morphine Market is supposed to register a healthy CAGR of 7.20% during the forecast time frame. The market development is fundamentally credited to the rising remedy of pain relievers for different diseases like cardiovascular problems, joint inflammation, or malignant growth. The developing geriatric populace additionally prompts an expansion in the patient populace and expanded market entrance by the market players.

Morphine is much of the time viewed as one of the most proficient painkillers. Likewise, its utilization in the therapy of extreme or constant torment related to cutting-edge medical circumstances is generally acknowledged in many nations of the world. Moreover, cardiovascular sicknesses guaranteed north of 801,000 lives in the US in the year 2014. Likewise, the rising use of pain relievers to ease torment in medical procedures is supposed to fuel the worldwide medical morphine market development. The ascent in the utilization of morphine for torment treatment is a key element adding to the market's development. Additionally, its utilization in the treatment of extreme and persistent agony related to a high-level medical condition is generally acknowledged in many regions across the globe. In addition, the expanded predominance of muscular diseases like elbow torment, joint pain, fibromyalgia, and osteoporosis is the key explanation driving the medical morphine market esteem extension.

Market Segmentation

The global medical morphine market is segmented into the distribution channel, application, route of administration, and end-user.

The route of administration segment is further bifurcated into Oral and Injectables types. The distribution channel segment is classified into Online pharmacy, Hospital pharmacy, Retail pharmacy, and Others.

The application segment is further classified into Myocardial infarction, Diarrhea, Arthritis, Kidney stones, Cancer, and Others. By end-user, the market is categorized into Ambulatory surgical centers, Hospitals and clinics, and home care.

Regional Analysis

The Americas is likely to lead the market. The expanded recurrence of joint pain or other fiery circumstances, and a rising geriatric populace, are supposed to support the market development in the American region. Also, factors like expanded endeavors by the public authority and ventures for innovative work in creative medical therapy options are supposed to help the development of the medical morphine market in the region.

The expansion in cardiovascular issues and joint inflammation is projected to straightforwardly affect restorative morphine interest, which is utilized to decrease joint agony and post-careful distress. Europe is supposed to be the second-biggest medical morphine market and may possess a sizable extent of the worldwide market over the forecast years. The European market is probably going to grow at a consistent speed through the forecast years, considering the productive extension of the medical care industry and the rising rates of joint pain. Besides, the rising provocative sicknesses, and a geriatric populace that prompts an expansion in the understanding pool, are powering market extension.

Over the forecast years, the Asia Pacific region is anticipated to be the fastest-developing morphine market. The rising rate of constant diseases like cardiovascular issues is one of the essential variables of market development. China is anticipated to be the quickest developing country, due to a growing populace, eventually rising patient pool, and the availability of inventive treatment choices. Likewise, expanded well-being consumption in the space is supporting the development of the Asia Pacific medical morphine market.

Key Players

The key companies that offer medical morphine in the global market include Taj Pharmaceuticals Limited, Johnson Matthey Fine Chemicals, Alcaliber S.A, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Mallinckrodt Pharmaceuticals, Purdue Pharma L.P., MANUS AKTTEVA BIOPHARMA LLP, Verve Health Care Ltd., and NORTHEAST PHARM

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
    • 2.2.1 RESEARCH OBJECTIVE
    • 2.2.2 ASSUMPTIONS
    • 2.2.3 LIMITATIONS

3. RESEARCH METHODOLOGY

  • 3.1 INTRODUCTION
  • 3.2 PRIMARY RESEARCH
  • 3.3 SECONDARY RESEARCH
  • 3.4 MARKET SIZE ESTIMATION

4. MARKET DYNAMICS

  • 4.1 DRIVERS
  • 4.2 RESTRAINTS
  • 4.3 OPPORTUNITIES
  • 4.4 CHALLENGES
  • 4.5 MACROECONOMIC INDICATORS
  • 4.6 TECHNOLOGY TRENDS & ASSESSMENT

5. MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 VALUE CHAIN ANALYSIS
  • 5.3 INVESTMENT FEASIBILITY ANALYSIS
  • 5.4 PRICING ANALYSIS

6. GLOBAL MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1 INTRODUCTION
  • 6.2 ORAL
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 6.3 INJECTABLES
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 6.4 OTHERS
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030

7. GLOBAL MEDICAL MORPHINE MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 ARTHRITIS
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 7.3 CANCER
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 7.4 MYOCARDIAL INFARCTION
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 7.5 KIDNEY STONES
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 7.6 DIARRHEA
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 7.7 OTHERS
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030

8. GLOBAL MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL

  • 8.1 INTRODUCTION
  • 8.2 HOSPITAL PHARMACY
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 8.3 RETAIL PHARMACY
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 8.4 ONLINE PHARMACY
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 8.5 OTHERS
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030

9. GLOBAL MEDICAL MORPHINE MARKET, BY END-USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS & CLINICS
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 9.3 AMBULATORY SURGICAL CENTERS
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 9.4 HOMECARE
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
  • 9.5 OTHERS
  • MARKET ESTIMATES & FORECAST, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030

10 GLOBAL MEDICAL MORPHINE MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 AMERICAS
  • MARKET ESTIMATES & FORECAST, BY REGION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.2.1 NORTH AMERICA
  • MARKET ESTIMATES & FORECAST, BY COUNTRY, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
      • 10.2.1.1 U.S.
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
      • 10.2.1.2 CANADA
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.2.2 SOUTH AMERICA
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.3 EUROPE
  • MARKET ESTIMATES & FORECAST, BY REGION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.3.1 WESTERN EUROPE
  • MARKET ESTIMATES & FORECAST, BY COUNTRY, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
      • 10.3.1.1 GERMANY
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
      • 10.3.1.2 FRANCE
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
      • 10.3.1.3 U.K.
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
      • 10.3.1.4 ITALY
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
      • 10.3.1.5 SPAIN
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
      • 10.3.1.6 REST OF WESTERN EUROPE
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.3.2 EASTERN EUROPE
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.4 ASIA PACIFIC
  • MARKET ESTIMATES & FORECAST, BY COUNTRY, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.4.1 JAPAN
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.4.2 CHINA
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.4.3 INDIA
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.4.4 AUSTRALIA
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.4.5 REPUBLIC OF KOREA
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.4.6 REST OF ASIA PACIFIC
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.5 THE MIDDLE EAST & AFRICA
  • MARKET ESTIMATES & FORECAST, BY REGION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.5.1 UNITED ARAB EMIRATES
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.5.2 SAUDI ARABIA
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.5.3 OMAN
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.5.4 KUWAIT
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.5.5 QATAR
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
    • 10.5.6 REST OF THE MIDDLE EAST & AFRICA
  • MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
  • MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030

11 COMPANY LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS
  • 11.3 KEY DEVELOPMENT & STRATEGIES
    • 11.3.1 KEY DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 MALLINCKRODT PHARMACEUTICALS
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 APPLICATION OVERVIEW
    • 12.1.3 FINANCIALS
    • 12.1.4 SWOT ANALYSIS
  • 12.2 ALCALIBER S.A.
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 APPLICATION OVERVIEW
    • 12.2.3 FINANCIAL OVERVIEW
    • 12.2.4 KEY DEVELOPMENTS
    • 12.2.5 SWOT ANALYSIS
  • 12.3 PURDUE PHARMA L.P.
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 APPLICATION OVERVIEW
    • 12.3.3 FINANCIAL OVERVIEW
    • 12.3.4 KEY DEVELOPMENT
    • 12.3.5 SWOT ANALYSIS
  • 12.4 PFIZER INC.
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 APPLICATION/BUSINESS SEGMENT OVERVIEW
    • 12.4.3 FINANCIAL OVERVIEW
    • 12.4.4 KEY DEVELOPMENT
    • 12.4.5 SWOT ANALYSIS
  • 12.5 JOHNSON MATTHEY FINE CHEMICALS
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 APPLICATION OVERVIEW
    • 12.5.3 FINANCIAL OVERVIEW
    • 12.5.4 KEY DEVELOPMENTS
  • 12.6 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 APPLICATION OVERVIEW
    • 12.6.3 FINANCIAL OVERVIEW
    • 12.6.4 KEY DEVELOPMENTS
  • 12.7 VERVE HEALTH CARE LTD.
    • 12.7.1 OVERVIEW
    • 12.7.2 APPLICATION OVERVIEW
    • 12.7.3 FINANCIALS
    • 12.7.4 KEY DEVELOPMENTS
    • 12.7.5 SWOT ANALYSIS
  • 12.8 TAJ PHARMACEUTICALS LIMITED
    • 12.8.1 OVERVIEW
    • 12.8.2 APPLICATION OVERVIEW
    • 12.8.3 FINANCIALS
    • 12.8.4 KEY DEVELOPMENTS
    • 12.8.5 SWOT ANALYSIS
  • 12.9 NORTHEAST PHARM
    • 12.9.1 OVERVIEW
    • 12.9.2 APPLICATION OVERVIEW
    • 12.9.3 FINANCIALS
    • 12.9.4 KEY DEVELOPMENTS
    • 12.9.5 SWOT ANALYSIS
  • 12.10 MANUS AKTTEVA BIOPHARMA LLP
    • 12.10.1 OVERVIEW
    • 12.10.2 APPLICATION OVERVIEW
    • 12.10.3 FINANCIALS
    • 12.10.4 KEY DEVELOPMENTS
    • 12.10.5 SWOT ANALYSIS

13 APPENDIX

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제